Home › Funds › Bain Capital Life Sciences Investors, LLC › KLRA
Bain Capital Life Sciences Investors, LLC position in KLRA
KAILERA THERAPEUTICS INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 22,583,268 shares of KLRA (KAILERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$257.9M, representing 17.75% of its reported portfolio and ranking #1 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's KLRA position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in KLRA in Q2 2026 at 22,583,268 shares (US$497.5M). Across 2 filings, Bain Capital Life Sciences Investors, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 22,583,268 shares valued at US$257.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 22.58M | $497.51M | New |
| Q3 2026 | 22.58M | $257.90M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KLRA and 13F data
KLRA (KAILERA THERAPEUTICS INC) is a Health Care company. 134 other funds we track also report a position in KLRA — the largest reported positions include BAIN CAPITAL INVESTORS LLC (US$299.8M), RTW INVESTMENTS, LP (US$123.1M), Atlas Venture Life Science Advisors, LLC (US$59.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KLRA
- BAIN CAPITAL INVESTORS LLC 26.26M sh · $299.84M · Q3 2026
- RTW INVESTMENTS, LP 10.78M sh · $123.07M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 5.17M sh · $59.06M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 2.46M sh · $28.04M · Q3 2026
- Siren, L.L.C. 2.21M sh · $25.29M · Q3 2026
- Farallon Capital Management 1.10M sh · $24.23M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.10M sh · $24.23M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $12.12M · Q2 2026
- Trails Edge Capital Partners, LP 942.95K sh · $10.77M · Q3 2026
- Catalio Capital Management, LP 468.75K sh · $10.33M · Q2 2026
- a16z Capital Management, L.L.C. 140.00K sh · $3.08M · Q2 2026
- Avidity Partners Management LP 80.00K sh · $1.76M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held KLRA?
Bain Capital Life Sciences Investors, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Bain Capital Life Sciences Investors, LLC's current position in KLRA?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 22.58M shares of KLRA (KAILERA THERAPEUTICS INC), valued at $257.90M, representing 17.75% of its reported portfolio and ranking #1.
Has Bain Capital Life Sciences Investors, LLC been buying or selling KLRA?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in KLRA.
Which other funds hold KLRA?
Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, RTW INVESTMENTS, LP, Atlas Venture Life Science Advisors, LLC, among 134 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.